0001564590-21-061216.txt : 20211227 0001564590-21-061216.hdr.sgml : 20211227 20211227080549 ACCESSION NUMBER: 0001564590-21-061216 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211222 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211227 DATE AS OF CHANGE: 20211227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Metacrine, Inc. CENTRAL INDEX KEY: 0001634379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472297384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39512 FILM NUMBER: 211518935 BUSINESS ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-369-7800 MAIL ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 mtcr-8k_20211222.htm 8-K mtcr-8k_20211222.htm
false 0001634379 0001634379 2021-12-22 2021-12-22

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2021

 

Metacrine, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39512

47-2297384

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

3985 Sorrento Valley Blvd., Suite C

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 369-7800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

MTCR

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ 

 

 

 

 

 

 

Item 8.01 Other Events.

On December 22, 2021, Hubert Chen notified the Company that he will resign from his position as Chief Medical Officer, effective as of December 31, 2021. Dr. Chen’s resignation is not the result of any disagreement with the Company regarding its operations, policies or practices. The Company has issued a press release announcing Dr. Chen’s resignation. A copy of the press release is attached hereto as Exhibit 99.1

At-the-Market Offering Program Update

As previously reported, on October 4, 2021, the Company entered into a sales agreement with SVB Leerink LLC (“Leerink”), as agent, pursuant to which the Company may offer and sell Common Stock for aggregate gross sale proceeds of up to $50.0 million from time to time through Leerink under an “at-the-market” offering program. Since October 4, 2021, the Company has issued and sold an aggregate of 15,534,172 shares of Common Stock under its “at-the-market” offering program for aggregate net sale proceeds of approximately $21.7 million, after deducting sales commissions and related professional fees and services.

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

The following exhibit is furnished with this Current Report.

 

Exhibit

Number

 

Description

99.1

 

Press release issued on December 27, 2021.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Metacrine, Inc.

 

 

 

 

Date: December 27, 2021

 

By:

/s/ Catherine Lee

 

 

 

Catherine Lee

 

 

 

EVP, General Counsel and Corporate Secretary

 

2

 EX-99.1 2 mtcr-ex991_6.htm EX-99.1 mtcr-ex991_6.htm

Exhibit 99.1

 

METACRINE ANNOUNCES RESIGNATION OF CHIEF MEDICAL OFFICER

SAN DIEGO – December 27, 2021 - Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen’s resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine’s ongoing clinical trials and future clinical operations.

“We appreciate Hubert’s significant contributions during the last three years as we moved our pipeline through several important milestones,” said Preston Klassen, M.D., MHS, CEO, Metacrine. “Hubert has established a strong team in our R&D organization that will continue to serve us well as we focus our resources on moving our IBD program into the clinic. We wish Hubert success in his future endeavors.”

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat gastrointestinal and liver diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. To learn more, visit www.metacrine.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements about plans for initiating future clinical trials and studies. Words such as “may,” “will,” “expect,” “plan,” “aim,” “projected,” “likely,” “anticipate,” “estimate,” “intend,” “potential,” “prepare,” “perceived,” “believes” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Metacrine’s expectations and assumptions that may never materialize or prove to be incorrect. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks and uncertainties regarding regulatory approvals for MET409 or MET642; potential delays in initiating, enrolling or completing any clinical trials; potential adverse side effects or other safety risks associated with Metacrine’s product candidates; competition from third parties that are developing products for similar uses; and Metacrine’s ability to obtain, maintain and protect its intellectual property. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Metacrine’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021, and in Metacrine’s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as required by law, Metacrine assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Investor & Media Contact

Steve Kunszabo

Metacrine, Inc.

+1 (858) 369-7892

skunszabo@metacrine.com

 

 EX-101.SCH 3 mtcr-20211222.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mtcr-20211222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Central Index Key Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 mtcr-20211222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Dec. 22, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Entity Registrant Name Metacrine, Inc.
Document Period End Date Dec. 22, 2021
Entity Central Index Key 0001634379
Entity File Number 001-39512
Entity Incorporation State Country Code DE
Entity Tax Identification Number 47-2297384
Entity Address, Address Line One 3985 Sorrento Valley Blvd.
Entity Address, Address Line Two Suite C
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 369-7800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol MTCR
Security Exchange Name NASDAQ
XML 7 mtcr-8k_20211222_htm.xml IDEA: XBRL DOCUMENT 0001634379 2021-12-22 2021-12-22 false 0001634379 8-K 2021-12-22 Metacrine, Inc. DE 001-39512 47-2297384 3985 Sorrento Valley Blvd. Suite C San Diego CA 92121 (858) 369-7800 false false false false Common Stock, par value $0.0001 per share MTCR NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports mtcr-8k_20211222.htm mtcr-20211222.xsd mtcr-20211222_lab.xml mtcr-20211222_pre.xml mtcr-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mtcr-8k_20211222.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "mtcr-8k_20211222.htm" ] }, "labelLink": { "local": [ "mtcr-20211222_lab.xml" ] }, "presentationLink": { "local": [ "mtcr-20211222_pre.xml" ] }, "schema": { "local": [ "mtcr-20211222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mtcr", "nsuri": "http://www.metacrine.com/20211222", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20211222.htm", "contextRef": "C_0001634379_20211222_20211222", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20211222.htm", "contextRef": "C_0001634379_20211222_20211222", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.metacrine.com/20211222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-21-061216-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-061216-xbrl.zip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end